On July 30, 2025 Takeda (TOKYO:4502/NYSE:TAK) reported earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter (Press release, Takeda, JUL 30, 2025, View Source [SID1234654660]). The company expects these impacts to moderate in future quarters.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory and underscoring its commitment to delivering sustainable value through innovation. Most notably, both Phase 3 studies of oveporexton successfully met all primary and secondary endpoints, demonstrating statistically significant improvements across doses. These results reinforce the potential of oveporexton to transform the standard of care in narcolepsy type 1.
In addition, Takeda received U.S. FDA approval for GAMMAGARD LIQUID ERC and European Commission (EC) approval for ADCETRIS in new indications and presented promising clinical data for rusfertide at the 61st American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting Plenary Session. These developments underscore the strength of Takeda’s late-stage pipeline and its potential to drive future growth.
Takeda chief financial officer, Milano Furuta, commented:
"The impact of VYVANSE generic erosion on Takeda’s FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May.
"Our late-stage pipeline continues to advance with the announcement in July of positive results from two pivotal Phase 3 studies for oveporexton in narcolepsy type 1, with both studies meeting all primary and secondary endpoints. These results represent a significant scientific milestone, and we are very excited about the potential for our late-stage pipeline to deliver value to the patients we serve and to position Takeda for sustainable growth."
FINANCIAL HIGHLIGHTS for FY2025 Q1 Ended June 30, 2025
(Billion yen, except percentages and per share amounts)
FY2025 Q1
FY2024 Q1
vs. PRIOR YEAR
(Actual % change)
Revenue
1,106.7
1,208.0
-8.4%
Operating Profit
184.6
166.3
+11.0%
Net Profit
124.2
95.2
+30.4%
EPS (Yen)
79
61
+30.8%
Operating Cash Flow
215.4
170.3
+26.5%
Adjusted Free Cash Flow (Non-IFRS)
190.1
23.7
+703.6%
Core (Non-IFRS)
(Billion yen, except percentages and per share amounts)
FY2025 Q1
FY2024 Q1
vs. PRIOR YEAR
(Actual % change)
vs. PRIOR YEAR
(CER % change)
Revenue
1,106.7
1,208.0
-8.4%
-3.7%
Operating Profit
321.8
382.3
-15.8 %
-11.9%
Margin
29.1%
31.6%
-2.6 pp
―
Net Profit
237.0
276.8
-14.4%
-10.3%
EPS (Yen)
151
176
-14.1%
-10.0%
FY2025 Outlook (unchanged from May 2025)
(Billion yen, except percentages and per share amounts)
FY2025 FORECAST
FY2025
MANAGEMENT
GUIDANCE
Core Change at CER
(Non-IFRS)
Revenue
4,530.0
—
Core Revenue (Non-IFRS)
4,530.0
Broadly flat
Operating Profit
475.0
—
Core Operating Profit (Non-IFRS)
1,140.0
Broadly flat
Net Profit
228.0
—
EPS (Yen)
145
—
Core EPS (Yen) (Non-IFRS)
485
Broadly flat
Adjusted Free Cash Flow (Non-IFRS)
750.0-850.0
—
Annual Dividend per Share (Yen)
200
—
Additional Information About Takeda’s FY2025 Q1 Results
For more details about Takeda’s FY2025 Q1 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda’s FY2025 Q1 investor presentation (available at View Source).